Clinical evaluation of clotrimazole. A broad-spectrum antifungal agent.
The efficacy and safety of the broad-spectrum, topically applied antifungal agent clotrimazole were evaluated in two double-blind, multicentric trials. Ten investigators reported on a total of 1,361 cases in which a 1% solution or a 1% cream formulation was compared with its respective vehicle. Clotrimazole was therapeutically effective, as confirmed by mycological cure (negative microscopy and culture) and clinical improvement, in tinea pedis, tinea cruris, tinea corporis, pityriasis versicolor, and cutaneous candidasis. Furthermore, species identification established the efficacy of clotrimazole against Trichophyton rubrum, T mentagrophytes, Epidermophyton floccosum, Microsporum canis, Malassezia furfur (Pityrosporum orbiculare), and Candida albicans. Safety was demonstrated by the low incidence of possibly drug-related adverse experiences, namely, 19 (2.7%) of 699 patients who were treated with clotrimazole, of whom four (0.6%) discontinued treatment.
D002175:Candida / Q000187:drug effects; D002179:Candidiasis, Cutaneous / Q000188:drug therapy; D002986:Clinical Trials as Topic; D003022:Clotrimazole / Q000009:adverse effects / Q000627:therapeutic use*; D003881:Dermatomycoses / Q000188:drug therapy*; D004341:Drug Evaluation; D004821:Epidermophyton / Q000187:drug effects; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D008290:Malassezia / Q000187:drug effects; D008864:Microsporum / Q000187:drug effects; D014005:Tinea / Q000188:drug therapy; D014249:Trichophyton / Q000187:drug effects
D007093:Imidazoles; D003022:Clotrimazole